Loading
Launch Special: Analyst checkout is open at $29/mo (50% off regular price). Start checkout →
The 2026 Special 301 Report placed China, India, Russia, Venezuela, and four additional economies on the Priority Watch List while announcing out-of-cycle reviews for Brazil and Saudi Arabia. The report was released earlier than the § 182(a) statutory deadline to align with the USMCA joint review calendar and the upcoming §301 China review cycle. A notable cross-cutting addition is the elevation of generic-pharmaceuticals compulsory-licensing practices, which industry submissions linked to the §232 pharmaceutical tariff announcement. While Priority Watch List placement does not itself trigger tariff action, it serves as a formal predicate for subsequent § 301 investigations or WTO consultations.
The report is issued annually by statute on April 30 (§ 182(a)); the 2026 edition was accelerated to coincide with the USMCA joint review preparatory calendar and the upcoming Section 301 review cycle for China.
Priority Watch List placement does not itself trigger tariff action but serves as a predicate for subsequent § 301 investigations or WTO consultations. The 2026 report elevated generic-pharmaceuticals compulsory-licensing practices as a cross-cutting concern, reflecting pharmaceutical-industry lobbying after the Section 232 pharmaceutical tariffs.